StockData
BioLineRx Ltd. logo

BioLineRx Ltd. (BLRX) stock

BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 3/30
$1.15+0.03 (+2.68%)

Close on Nov 18, 2026Market cap $5.00MP/E –Yield –

Earnings

BioLineRx's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q2 FY2026
$300.00K
EPS, Q2 FY2026
$0.00
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of BioLineRx's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q2 FY2026ended Jun 30, 2026Aug 31, 2026before the open$300.00K–$0.00Release
Q4 FY2025ended Dec 31, 2025Mar 23, 2026before the open–––Release
Q4 FY2024ended Dec 31, 2024Mar 31, 2025before the open–––Release
Q2 FY2024ended Jun 30, 2024Aug 15, 2024before the open$5.40M–$0.00Release
Q4 FY2023ended Dec 31, 2023Mar 26, 2024before the open$4.80M––Release
Q4 FY2022ended Dec 31, 2022Mar 22, 2023before the open–––Release
Q4 FY2021ended Dec 31, 2021Mar 16, 2022before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

BioLineRx has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When BioLineRx puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases BioLineRx filed with the SEC as exhibits to Form 8-K or 6-K

  1. 6-K
  2. 6-K
  3. 6-K
  4. 6-K
  5. 6-K
  6. 6-K
  7. 6-K
  8. 6-K
  9. 6-K
  10. 6-K
  11. 6-K
  12. 6-K
  13. 6-K
  14. 6-K
  15. 6-K

See a number that looks wrong?